• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    XOMA Royalty Corporation - Common Stock (NQ:XOMA)

    28.37 +1.02 (+3.74%)
    Streaming Delayed Price Updated: 12:42 PM EDT, Mar 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about XOMA Royalty Corporation - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty to Present at Investor Conferences in March
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
    Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right 
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces CFO Transition
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Enters into Agreement to Acquire Generation Bio
    From Generation Bio Co.; XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
    From Mural Oncology plc
    Via GlobeNewswire
    News headline image
    Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
    From Mural Oncology plc
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
    From Mural Oncology plc
    Via GlobeNewswire
    News headline image
    XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
    From XOMA Royalty Corporation; LAVA Therapeutics N.V.
    Via GlobeNewswire
    News headline image
    XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
    From XOMA Royalty Corporation; LAVA Therapeutics
    Via GlobeNewswire
    News headline image
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
    HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value Right 
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
    From Kahn Swick & Foti, LLC
    Via GlobeNewswire
    News headline image
    XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
    XOMA Royalty adds milestone and royalty economics associated with two partnered assets 
    From XOMA Royalty Corporation; LAVA Therapeutics N.V.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.